Curematch

Executive Summary

CureMatch offers a clinical decision support platform that enables oncologists to identify optimal, genomically matched combination therapies for cancer patients. By analyzing a patient's tumor molecular profile, the system ranks approved and investigational drug combinations, potentially improving outcomes in precision oncology. Since its founding in 2015, the company has achieved regulatory approval (stage: Approved), positioning it as a credible tool for treatment planning in both community and academic cancer centers. CureMatch addresses the growing need for personalized cancer care as genomic testing becomes more widespread, though the platform's adoption depends on integration with electronic health records and clinician buy-in. The company operates in the competitive digital health space but benefits from a unique focus on combination therapies rather than single-agent matching.

Upcoming Catalysts (preview)

• Q3 2026Partnership announcement with a major cancer center or hospital network70% success
• Q4 2026Publication of real-world evidence study demonstrating improved outcomes60% success
• Q1 2027Expansion into new disease indication or geographic market50% success